Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 728,656,576
  • Shares Outstanding, K 950,405
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • 60-Month Beta 0.37
  • Price/Sales 20.47
  • Price/Cash Flow 99.12
  • Price/Book 55.70
Trade LLY with:

Options Overview Details

View History
  • Implied Volatility 25.11% ( -0.64%)
  • Historical Volatility 30.38%
  • IV Percentile 31%
  • IV Rank 31.03%
  • IV High 38.67% on 10/26/23
  • IV Low 19.01% on 09/01/23
  • Put/Call Vol Ratio 0.65
  • Today's Volume 34,852
  • Volume Avg (30-Day) 34,381
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 277,483
  • Open Int (30-Day) 277,122

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 2.65
  • Number of Estimates 8
  • High Estimate 2.95
  • Low Estimate 2.28
  • Prior Year 2.11
  • Growth Rate Est. (year over year) +25.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
718.30 +8.28%
on 04/25/24
795.50 -2.23%
on 04/30/24
-6.44 (-0.82%)
since 04/05/24
3-Month
718.30 +8.28%
on 04/25/24
800.78 -2.87%
on 03/04/24
+52.39 (+7.22%)
since 02/07/24
52-Week
419.80 +85.27%
on 05/25/23
800.78 -2.87%
on 03/04/24
+349.96 (+81.80%)
since 05/05/23

Most Recent Stories

More News
Why Eli Lilly Stock Jumped by 4% Today

The company's payout is far from the only reason investors like the stock these days, but it certainly helps.

LLY : 777.77 (+1.45%)
2 Top Stocks That Could Make You Richer in 2024

Here are a couple of great ideas on where to invest your money today.

GOOGL : 171.25 (+1.87%)
GOOG : 172.98 (+1.85%)
LLY : 777.77 (+1.45%)
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years

These stocks have rock-solid businesses and they have impressive track records for paying dividends.

LLY : 777.77 (+1.45%)
KO : 62.62 (+0.43%)
TD : 55.32 (+0.64%)
3 No-Brainer Stocks to Buy in May

These great stocks are great picks for investors as spring winds down.

LLY : 777.77 (+1.45%)
PFE : 27.77 (-1.38%)
VRTX : 410.24 (+1.92%)
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making

Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.

JPM : 191.75 (-0.13%)
LLY : 777.77 (+1.45%)
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.

LLY : 777.77 (+1.45%)
PFE : 27.77 (-1.38%)
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?

The anti-obesity medication stock is way up, and there could be more fuel in the tank.

NVO : 127.29 (+2.17%)
VKTX : 79.61 (+1.79%)
LLY : 777.77 (+1.45%)
Why Amgen Stock Zoomed Nearly 12% Higher Today

The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.

NVO : 127.29 (+2.17%)
LLY : 777.77 (+1.45%)
AMGN : 300.30 (+0.27%)
This Is a Huge Sigh of Relief for Novo Nordisk Investors

The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.

LLY : 777.77 (+1.45%)
NVO : 127.29 (+2.17%)
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?

The company seems to be going from strength to strength lately.

LLY : 777.77 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 800.85
2nd Resistance Point 789.97
1st Resistance Point 783.87
Last Price 777.77
1st Support Level 766.89
2nd Support Level 756.01
3rd Support Level 749.91

See More

52-Week High 800.78
Last Price 777.77
Fibonacci 61.8% 655.25
Fibonacci 50% 610.29
Fibonacci 38.2% 565.33
52-Week Low 419.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar